SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

07 Aug 2023 Evaluate
With no major difference for the quarter endedJune 2023 , the total revenue stood at Rs. 8840.70  millions.A slender decline of -18.25% was recorded to Rs. 1875.82  millions from Rs. 2294.54 millions in the corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 2945.69 millions from 3445.95 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 8840.70 8568.98 3.17 8840.70 8568.98 3.17 36165.28 44007.08 -17.82
Other Income 352.07 743.92 -52.67 352.07 743.92 -52.67 2404.64 2239.40 7.38
PBIDT 2945.69 3445.95 -14.52 2945.69 3445.95 -14.52 12590.13 17345.79 -27.42
Interest 15.96 9.00 77.33 15.96 9.00 77.33 74.14 52.40 41.49
PBDT 2929.73 3436.95 -14.76 2929.73 3436.95 -14.76 11951.38 17293.39 -30.89
Depreciation 389.82 349.11 11.66 389.82 349.11 11.66 1467.36 1102.96 33.04
PBT 2539.91 3087.84 -17.74 2539.91 3087.84 -17.74 10484.02 16190.43 -35.25
TAX 664.09 793.30 -16.29 664.09 793.30 -16.29 2725.76 4068.88 -33.01
Deferred Tax 75.29 38.90 93.55 75.29 38.90 93.55 -27.99 140.08 -119.98
PAT 1875.82 2294.54 -18.25 1875.82 2294.54 -18.25 7758.26 12121.55 -36.00
Equity 164.70 164.65 0.03 164.70 164.65 0.03 164.70 164.30 0.24
PBIDTM(%) 33.32 40.21 -17.14 33.32 40.21 -17.14 34.81 39.42 -11.68

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×